Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory Carter

Showing results (111-120 of 133) with videos related to

Pageof 14
Sort By:
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|November 6, 2025
ALSUntangled #81: Pyridostigmine (mestinon<sup>®</sup>)Nadia Mansoor, Terry Heiman-Patterson, Eva L Feldman, et al.
Drug and Alcohol Review|October 6, 2020
Clinical and demographic characteristics of people who smoke versus inject crystalline methamphetamine in Australia: Findings from a pharmacotherapy trialRebecca McKETIN, Brendan Quinn, Peter Higgs, et al.
The British Journal of Psychiatry : the Journal of Mental Science|January 7, 2025
Effect of ketamine on anxiety: findings from the Ketamine for Adult Depression StudyNatalie T Mills, Stevan Nikolin, Nick Glozier, et al.
The British Journal of Psychiatry : the Journal of Mental Science|March 31, 2026
Effect of ketamine on anxiety: findings from the Ketamine for Adult Depression Study - RETRACTIONNatalie T Mills, Stevan Nikolin, Nick Glozier, et al.
Journal of Affective Disorders|May 29, 2025
Economic evaluation of subcutaneous ketamine injections for treatment resistant depression: A randomised, double-blind, active-controlled trial - The KADS studyMary Lou Chatterton, Johana Kevin Perez, Thao Thai, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
WSB.<i>APP/PS1</i> mice develop age-dependent cerebral amyloid angiopathy, cerebrovascular deficits, and white matter damage, which are modified by humanized <i>APOE</i> allelesKristen D Onos, Olivia J Marola, Asli Uyar, et al.
The British Journal of Psychiatry : the Journal of Mental Science|July 6, 2026
Effectiveness and safety of repeat dose subcutaneous ketamine for treatment-resistant depression, and the impact of prior ketamine treatment: open label extension of the KADS studyNick Glozier, Richard Morris, Elizabeth Stratton, et al.
Eclinicalmedicine|July 26, 2021
N-acetylcysteine (NAC) for methamphetamine dependence: A randomised controlled trialRebecca McKetin, Olivia M Dean, Alyna Turner, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|March 4, 2026
ALSUntangled #82: N-acetylcysteineSandeep Yerraguntla, Bhavya Bakshi, Keshav Chandran, et al.
The British Journal of Psychiatry : the Journal of Mental Science|October 14, 2024
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial - CORRIGENDUMColleen Loo, Nick Glozier, David Barton, et al.
Pageof 14

Showing results (111-120 of 133) with videos related to

Sort By:
Pageof 14
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|November 6, 2025
ALSUntangled #81: Pyridostigmine (mestinon<sup>®</sup>)Nadia Mansoor, Terry Heiman-Patterson, Eva L Feldman, et al.
Drug and Alcohol Review|October 6, 2020
Clinical and demographic characteristics of people who smoke versus inject crystalline methamphetamine in Australia: Findings from a pharmacotherapy trialRebecca McKETIN, Brendan Quinn, Peter Higgs, et al.
The British Journal of Psychiatry : the Journal of Mental Science|January 7, 2025
Effect of ketamine on anxiety: findings from the Ketamine for Adult Depression StudyNatalie T Mills, Stevan Nikolin, Nick Glozier, et al.
The British Journal of Psychiatry : the Journal of Mental Science|March 31, 2026
Effect of ketamine on anxiety: findings from the Ketamine for Adult Depression Study - RETRACTIONNatalie T Mills, Stevan Nikolin, Nick Glozier, et al.
Journal of Affective Disorders|May 29, 2025
Economic evaluation of subcutaneous ketamine injections for treatment resistant depression: A randomised, double-blind, active-controlled trial - The KADS studyMary Lou Chatterton, Johana Kevin Perez, Thao Thai, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
WSB.<i>APP/PS1</i> mice develop age-dependent cerebral amyloid angiopathy, cerebrovascular deficits, and white matter damage, which are modified by humanized <i>APOE</i> allelesKristen D Onos, Olivia J Marola, Asli Uyar, et al.
The British Journal of Psychiatry : the Journal of Mental Science|July 6, 2026
Effectiveness and safety of repeat dose subcutaneous ketamine for treatment-resistant depression, and the impact of prior ketamine treatment: open label extension of the KADS studyNick Glozier, Richard Morris, Elizabeth Stratton, et al.
Eclinicalmedicine|July 26, 2021
N-acetylcysteine (NAC) for methamphetamine dependence: A randomised controlled trialRebecca McKetin, Olivia M Dean, Alyna Turner, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|March 4, 2026
ALSUntangled #82: N-acetylcysteineSandeep Yerraguntla, Bhavya Bakshi, Keshav Chandran, et al.
The British Journal of Psychiatry : the Journal of Mental Science|October 14, 2024
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial - CORRIGENDUMColleen Loo, Nick Glozier, David Barton, et al.
Pageof 14